Pharma Focus Asia

Pfizer and Astellas Pharma Announce FDA Priority Review for XTANDI®

Thursday, August 24, 2023

Pfizer and Astellas Pharma have recently announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental new drug application (sNDA) for XTANDI® (enzalutamide).

This drug is being considered for the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC), which is also referred to as non-metastatic hormone-sensitive prostate cancer (nmHSPC), especially in cases with high-risk biochemical recurrence (BCR).

If the sNDA is approved, XTANDI will become the first novel hormone therapy to gain FDA approval for treating this earlier stage of prostate cancer. The primary aim of this treatment is to delay the spread of cancer cells to other parts of the body. 

Clinical trials have demonstrated that the addition of XTANDI to leuprolide (a common hormonal therapy) provides greater clinical benefits compared to using placebo in combination with leuprolide.

The trial successfully achieved its primary goal of showing improved metastasis-free survival (MFS) for the group that received XTANDI plus leuprolide. This combination demonstrated a significant 58 percent decrease in the risk of metastasis (the spread of cancer) or death when compared to the placebo plus leuprolide group.

magazine-slider-image
magazine-slider-image
Cytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024